Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05050370
Other study ID # UW20-019
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 4, 2021
Est. completion date December 2021

Study information

Verified date September 2021
Source The University of Hong Kong
Contact Agnes Lai, PhD
Phone 852-3917-6328
Email agneslai@hku.hk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Lung cancer is one of the most common cancer diseases, globally and locally. Several health benefits of increased physical activity (PA) have been reported for people with cancer. PA plays a critical role across the cancer trajectory, from prevention through to post-diagnosis and has been proposed as an alternative for improving physical and psychosocial health outcomes, reducing cancer recurrence, and cancer-specific and all-cause mortality. Although there are a variety of exercise intervention programs for cancer patients, those programs were quite intensive, requiring individuals to commit extra time and effort. Feeling of overwhelmed appointments, lack of time, other barriers, including high cost and limited access to facilities are the most frequently reported barriers that prevent people from starting and maintaining exercise. Hence, the investigators propose to use a brief messaging lifestyle modification intervention program to incorporating simple and easy-to-do patient-centred home-based lifestyle-integrated exercise into daily activities of patients with lung cancer. The aims are to explore the feasibility of using instant messaging to enhance physical activity and improve their fatigue, emotion and quality of life, and obtain feedback from patients for intervention and study design improvement.


Description:

Lung cancer is one of the most common cancer, globally and locally. Patients with lung cancer are in a uniquely challenging situation in their disease, comorbidities, and treatment that may lead to worsened symptoms and many negative health consequences, including fatigue, irritability, and impaired daytime functioning. Physical activity (PA) is defined as 'any bodily movement produced by skeletal muscle that results in energy expenditure'. Several health benefits of increased PA have been reported for people with cancer. PA plays a critical role across the cancer trajectory, from prevention through to postdiagnosis and has been proposed as an alternative for improving physical and psychosocial health outcomes, reducing cancer recurrence, and cancer-specific and all-cause mortality. Although there are a variety of exercise intervention programs for cancer patients, those programs were quite intensive, requiring individuals to commit extra time and effort. Most clinicians underutilise exercise therapy, regardless of its low-cost way to improve symptoms and potential health outcomes. Feeling of overwhelmed appointments, lack of time, other barriers, including high cost and limited access to facilities are the most frequently reported barriers that prevent people from starting and maintaining exercise. Low motivation, fear to exercise, lack of knowledge about benefits are the most common barriers of engaging in physical activity for cancer patients. Hence, the current proposal is to use a brief messaging lifestyle modification intervention program to incorporating simple and easy-to-do patient-centred home-based lifestyle-integrated exercise (light to moderate physical activity) into daily activities of patients with lung cancer. The aims are to explore the feasibility of using instant messaging to enhance physical activity and improve their fatigue, emotion and quality of life, and obtain feedback from patients for intervention and study design improvement.


Recruitment information / eligibility

Status Recruiting
Enrollment 16
Est. completion date December 2021
Est. primary completion date December 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion criteria - Aged 18 years and above; - Diagnosis of non-small cell lung cancer or small cell lung cancer - Fatigue symptom score =4 out of 10 - Self-reported engagement of <150 minutes of moderate-intensity PA each week - Ambulatory and capable of all self-care activities - Either undergoing or finished oncology therapy and/or support care - Mentally, cognitively and physically fit to join the trial - Able to speak and read Chinese; - Willing to complete the patient-reported outcome questionnaire - Completion of the Physical Activity Readiness Questionnaire - Possession of a smartphone with instant messaging functions such as WhatsApp or WeChat. Exclusion criteria - Those preparing for lung operation - Skeletal fragility - Serious active infection - Inability to walk - Severe respiratory insufficiency - Uncontrolled pain - Diagnosed psychiatric illness such as major depressive disorder

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Brief messaging and personalized support
Patients will receive (i) a face-to-face group session and a package of instant messages related to lifestyle-integrated exercise (including breathing, balance, aerobic, strength, stretching exercises), cancer-related care information and support.

Locations

Country Name City State
Hong Kong Queen Mary Hospital Hong Kong

Sponsors (1)

Lead Sponsor Collaborator
The University of Hong Kong

Country where clinical trial is conducted

Hong Kong, 

References & Publications (2)

Gopalakrishnan S, Takemoto L. Binding of actin to lens alpha crystallins. Curr Eye Res. 1992 Sep;11(9):929-33. — View Citation

Peddle-McIntyre CJ, Singh F, Thomas R, Newton RU, Galvão DA, Cavalheri V. Exercise training for advanced lung cancer. Cochrane Database Syst Rev. 2019 Feb 11;2:CD012685. doi: 10.1002/14651858.CD012685.pub2. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in fatigue level at 6 week measured by Functional Assessment of Cancer Therapy - Fatigue subscale, the higher scores, the more fatigue. Baseline and 6 weeks
Secondary Change in Anxiety and depressive symptoms at 6 weeks measured by Hospital Anxiety and Depression Scale, Each item is answered on a 4-point scale (0-3). The scores for the seven questions on depression are added together to obtain a score ranged from 0 to 21. The higher score the more depressed. The scores for the seven questions on anxiety are added together to obtain a score ranged from 0 to 21. The higher score the more anxiety and depression symptoms. Baseline and 6 weeks
Secondary Change in sleep quality at 6 weeks measured by the Pittsburgh sleep quality index . The higher the score, the worse the quality. Baseline and 6 weeks
Secondary Change in Health-related quality of life at 6 weeks measured by the European Organization for Research and Treatment of Cancer and Lung Module. The higher scores the worse the quality. Baseline and 6 weeks
Secondary Change in Subjective Happiness at 6 weeks measured by Subjective Happiness Scale. The higher scores the more happy. Baseline and 6 weeks
Secondary Change in Pain at 6 weeks measured by a question with a scale from 0 to 10; a score of "0" indicates no pain at all, a score of "10" indicates severe pain. The higher score, the more pain. Baseline and 6 weeks
Secondary Change in dyspnea at 6 weeks measured by a question with a scale from 0 to 10; a score of "0" indicates no dyspnea at all, a score of "10" indicates severe dyspnea. The higher score, the more dyspnea. Baseline and 6 weeks
Secondary Change in activity level at 6 weeks measured by pedometer Baseline and 6 weeks
Secondary Change in hand grip strength at 6 weeks measured by a dynamometer Baseline and 6 weeks
Secondary Change in balance at 6 weeks measured by single leg stand test Baseline and 6 weeks
Secondary Change in flexibility at 6 weeks measured by chair sit and reach test Baseline and 6 weeks
Secondary Change in sleep quality with objective measurement at 6 weeks measured by activity monitor on duration of sleep and awake intervals Baseline and 6 weeks
Secondary Change in physical activity level with objective measurement at 6 weeks measured by accelerometer on the daily walking steps Baseline and 6 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases